Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

(NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity.

Real-time index price for Nasdaq Composite [TR] (XCMP), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Wegovy is suggested to be started at 0.25 mg for 4 weeks. Patients then gradually increase the dosage to 0.5 mg ... The daily ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...

This article looks at how long you can take Wegovy for weight loss, what results you might have, and what happens if you stop using it. No. The recommended starting dose for Wegovy is 0.25 ...